AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 161 min read$CRSP

George Simeon sold $720K of CRSP

George Simeon sold 14,514 shares of CRISPR Therapeutics AG (CRSP) at $49.63 ($0.72M total) on 2026-10-14 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · George Simeon
Published Oct 16, 2026, 9:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 9:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CRSP
Bearish
medium confidence
Mentioned
$CRSP
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRSPBearishLow
01

Why it matters

The disclosed sale may cause modest short-term price pressure but is unlikely to affect long-term outlook.

02

Market read

A director's insider sale of $720K is a modest, primary-source event that may slightly depress the stock.

03

What to watch

Potential tax planning or diversification needs of the director.

Relevance 4/10Novelty 4/10Timing: filing date 2026-10-16

Background

SEC Form 4 filing discloses an insider transaction by a director of CRISPR Therapeutics.

Company-level read

Ticker impact

$CRSPBearishMedium confidence
Context

Director George Simeon sold 14,514 shares for $720,373 via a 10b5-1 plan, reducing his stake to 15,486 shares.

Expected impact

likely slight downward pressure as investors price in the insider sell

Evidence & confidence

The sale is a routine insider transaction of modest size; markets typically react modestly to director sales.

Market effects

Sector

minimal impact on biotech sector

Regional

none

Global

none

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company fundamentals.

Key entities

  • company
    CRISPR Therapeutics AG

    Biotech firm developing CRISPR gene-editing therapies.

  • person
    George Simeon

    Director of CRISPR Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CRSP insider trading history →

Related articles

OCT 28
$PRMEHighAI 8/10

PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits

Shares of gene-editing companies, including Prime Medicine (PRME), Beam Therapeutics, Intellia Therapeutics (NTLA), Editas Medicine (EDIT), and CRISPR Therapeutics (CRSP), rose after the FDA issued draft guidance to expedite personalized treatments for rare genetic diseases. The new approach allows one application for multiple versions of the same gene-editing treatment. PRME gained 20%, with other companies seeing 4-14% increases.

stocktwits.com2 min
OCT 24
$CRSPMedAI 8/10

Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More

CRISPR Therapeutics (CRSP) reports promising Phase 1a trial data for CTX310, a gene-editing therapy for high LDL and TG levels, with potential market of 40M+ U.S. patients. The company also shares Casgevy's rights with Vertex (VRTX). CTX310's Phase 1b results are expected in November. CRISPR's pipeline includes other candidates like CTX611, but faces risks of setbacks and market adoption challenges.

finance.yahoo.com3 min